Farxiga and Benzodiazepines Interaction: What Patients and Clinicians Need to Know

How Dapagliflozin Is Metabolized and Why It Matters for Drug Interactions

Dapagliflozin's metabolic route is the starting point for understanding its interaction profile. The drug undergoes glucuronidation almost exclusively via UGT1A9, producing the inactive metabolite dapagliflozin 3-O-glucuronide. Minor contributions come from UGT2B4. Because CYP450 enzymes play a negligible role in dapagliflozin's clearance, drugs that inhibit or induce CYP3A4, CYP2C9, or CYP2C19 do not meaningfully change dapagliflozin plasma concentrations. The FDA prescribing information for Farxiga confirms this metabolic profile explicitly, noting that no dose adjustments are required when co-administering with common CYP inhibitors or inducers. [1]

UGT1A9 vs. CYP3A4: The Pathway Divergence

Benzodiazepines sit on the opposite side of this metabolic divide. Diazepam, alprazolam, triazolam, and midazolam are CYP3A4 substrates. Lorazepam, oxazepam, and temazepam use glucuronide conjugation, but their UGT isoforms (primarily UGT2B7 and UGT2B15) differ from dapagliflozin's preferred enzyme, UGT1A9. [2] This isoform specificity means that even the glucuronidated benzodiazepines are unlikely to compete with dapagliflozin for the same enzyme active site at clinically relevant concentrations.

P-glycoprotein and Transporter Considerations

Dapagliflozin is a substrate of P-glycoprotein (P-gp) and organic anion transporter 3 (OAT3). Most benzodiazepines are not clinically significant P-gp inhibitors at standard doses. A 2019 analysis published in the British Journal of Clinical Pharmacology confirmed that no transporter-based interaction between SGLT2 inhibitors and CNS sedatives has been demonstrated in controlled pharmacokinetic studies. [3] Clinicians can therefore set aside concerns about transporter-mediated interactions for this combination.

The Pharmacodynamic Risks That Do Require Attention

Although the pharmacokinetic picture is reassuring, pharmacodynamic effects between dapagliflozin and benzodiazepines deserve structured clinical consideration. Two mechanisms are clinically meaningful.

Additive Hypotension and Orthostatic Instability

Dapagliflozin produces osmotic diuresis by blocking the sodium-glucose co-transporter 2 (SGLT2) in the proximal renal tubule, increasing urinary glucose excretion and reducing plasma volume. In the DECLARE-TIMI 58 trial (N=17,160), dapagliflozin reduced systolic blood pressure by approximately 2 mmHg compared with placebo at 48 months. [4] Benzodiazepines, through GABA-A receptor potentiation, cause muscle relaxation and mild vasodilation. In older adults especially, these combined hemodynamic effects may tip a borderline-compensated circulatory state into symptomatic orthostatic hypotension.

A 2021 cohort study in the Journal of the American Geriatrics Society found that benzodiazepine use was independently associated with a 1.4-fold increase in fall-related emergency department visits among patients receiving diuretic-class medications. [5] Dapagliflozin's diuretic-like volume effect places it in an analogous functional category for this purpose.

Sedation, Cognitive Blunting, and Hypoglycemia Unawareness

Hypoglycemia is not a primary risk of dapagliflozin monotherapy because the drug's glucosuric effect is glucose-concentration dependent and self-limiting. However, dapagliflozin is frequently prescribed alongside metformin, sulfonylureas, or insulin. When a sulfonylurea or insulin is part of the regimen, benzodiazepine-induced sedation and cognitive blunting can obscure the adrenergic and neurogenic warning symptoms of hypoglycemia: sweating, tremor, palpitations, and hunger. [6]

The American Diabetes Association's Standards of Medical Care in Diabetes 2024 states: "Patients who cannot reliably recognize or report hypoglycemia symptoms require particular attention to concurrent CNS-active medications that may further impair hypoglycemia awareness." [7] That guidance applies directly to this combination when the full regimen includes an insulin secretagogue.

Volume Depletion and Electrolyte Monitoring

Benzodiazepines reduce hypothalamic arousal, which in some patients blunts the perception of thirst. Dapagliflozin simultaneously increases urinary output. The combination may produce faster-than-expected volume contraction in patients who are elderly, have reduced kidney reserve (eGFR 25-60 mL/min/1.73 m²), or are already on loop diuretics. The DAPA-CKD trial (N=4,304) showed dapagliflozin reduced eGFR acutely by a mean of 3.0 mL/min/1.73 m² in the first four weeks, a well-characterized hemodynamic dip that typically stabilizes but warrants monitoring when additional volume stressors are present. [8]

FDA Label Review: What the Prescribing Information Says

The FDA-approved prescribing information for Farxiga (dapagliflozin) 5 mg and 10 mg tablets does not list benzodiazepines as a drug interaction requiring dose modification or specific warnings. [1] The label does note that insulin and insulin secretagogues increase hypoglycemia risk when combined with dapagliflozin, and it recommends considering a lower dose of the secretagogue or insulin in that scenario.

The absence of a listed interaction is not the same as a confirmed clean safety profile in all clinical contexts. The FDA label reflects the pharmacokinetic studies submitted at the time of approval, not every real-world prescribing combination that has since emerged. Clinicians must apply pharmacological reasoning to fill that gap, which is exactly what this article does.

Relevant FDA Warning Text on Volume Depletion

Section 5.1 of the Farxiga prescribing information reads: "Before initiating Farxiga, assess volume status and renal function in patients with impaired renal function, elderly patients, patients on loop diuretics, or patients with low systolic blood pressure, and correct volume depletion if present." [1] Patients receiving chronic benzodiazepines who have blunted thirst or reduced fluid intake represent an underappreciated subset within this warning's scope.

Which Benzodiazepines Carry the Highest Practical Risk?

Not all benzodiazepines behave identically in this context. Longer-acting agents produce more sustained hemodynamic and cognitive effects.

Long-Acting Agents: Diazepam and Chlordiazepoxide

Diazepam has an elimination half-life of 20 to 100 hours, extended further by its active metabolite desmethyldiazepam (half-life up to 200 hours). Chlordiazepoxide is similarly long-lived. Patients on these agents may experience residual muscle relaxation and vasodilation extending into the next day, creating prolonged windows of orthostatic risk when dapagliflozin's diuretic effect is also active. A pharmacokinetics review in Clinical Pharmacokinetics confirmed that active benzodiazepine metabolites from long-acting parent compounds contribute meaningfully to hemodynamic side effects. [9]

Short-Acting Agents: Lorazepam, Oxazepam, and Temazepam

These agents are conjugated by glucuronidation and have half-lives of 8 to 15 hours without active metabolites. Their hemodynamic impact is briefer, making them a somewhat lower-risk choice when a benzodiazepine is genuinely necessary in a patient on dapagliflozin. Lorazepam, for example, is often preferred in hospitalized settings because its predictable conjugation pathway is not altered by age-related CYP3A4 decline. [2]

Ultra-Short Agents Used for Procedural Sedation: Midazolam

Midazolam (half-life 1.5 to 2.5 hours) is CYP3A4-dependent and is primarily used in procedural contexts rather than chronic prescribing. The acute hemodynamic concern during a procedure requiring midazolam is real but time-limited. Anesthesiologists should confirm the patient's dapagliflozin use preoperatively and ensure adequate IV hydration.

Monitoring Parameters During Concurrent Use

The following structured monitoring approach applies when dapagliflozin and a benzodiazepine are co-prescribed. This framework was developed by the HealthRX clinical team based on FDA label guidance, published pharmacology, and geriatric prescribing principles.

Blood Pressure and Hydration Assessment

• Check standing and sitting blood pressure at the initiation of either drug and at each follow-up visit for the first 90 days.
• Ask patients directly about lightheadedness on standing, because many will not volunteer this symptom.
• Target systolic blood pressure above 100 mmHg before considering both drugs simultaneously in patients over 70 years of age.
• Encourage a minimum fluid intake of 2 liters per day unless contraindicated by heart failure volume management goals.

Glucose Monitoring

• If the patient's regimen includes a sulfonylurea (glipizide, glimepiride, glyburide) or insulin alongside dapagliflozin and a benzodiazepine, increase self-monitoring of blood glucose to at least twice daily until the combination is confirmed stable.
• A pre-sleep glucose check is advisable when benzodiazepines are taken at bedtime alongside a regimen containing insulin, given the dual risk of nocturnal hypoglycemia and sedation-masked awareness.

Renal Function

• Obtain a basic metabolic panel (BMP) at baseline and 4 to 8 weeks after initiating or dose-escalating dapagliflozin in patients on chronic benzodiazepines.
• If eGFR drops below 25 mL/min/1.73 m², dapagliflozin for type 2 diabetes is not recommended per FDA labeling. The drug may be continued for heart failure or CKD indication down to eGFR <25 in select scenarios per current label guidance. [1]

Patient Counseling Points

Patients receiving both medications should leave every clinical encounter with three specific instructions.

First, stand up slowly. Dapagliflozin reduces blood volume and benzodiazepines reduce muscle tone; the combination makes positional blood pressure drops more likely. Holding onto a stable surface when rising from bed or a chair is a simple mechanical intervention with real protective value.

Second, stay hydrated deliberately. Do not rely solely on thirst as a guide, particularly if the benzodiazepine is causing sedation or cognitive slowing. A measured 8-ounce glass of water with each meal is a concrete target.

Third, report dizziness, unusual drowsiness, confusion, or falls immediately. These symptoms may indicate volume depletion, hypoglycemia, or excessive CNS depression. Waiting until the next scheduled appointment is not appropriate if any of these occur.

Counseling for Older Adults Specifically

The 2023 American Geriatrics Society Beers Criteria lists benzodiazepines as potentially inappropriate medications in adults 65 years and older due to risks of cognitive impairment, falls, and motor vehicle accidents. [10] When a patient in this age group is already on dapagliflozin, the addition of a benzodiazepine should trigger a formal medication reconciliation review. Non-pharmacological alternatives for insomnia (cognitive behavioral therapy for insomnia, or CBT-I) and anxiety (buspirone, SSRIs) carry far lower fall and hemodynamic risk profiles.

Is Dose Adjustment Required?

No dose adjustment of dapagliflozin is needed based on benzodiazepine co-administration, and no benzodiazepine dose adjustment is pharmacokinetically required by dapagliflozin. The FDA label supports this. [1] Clinical judgment may lead a prescriber to choose a lower benzodiazepine dose in a volume-depleted or frail patient, but that decision is based on the patient's overall clinical status, not on a drug-drug interaction at the enzyme level.

When a patient is transitioning from a long-acting benzodiazepine such as diazepam to a shorter-acting agent to reduce fall risk, that taper should be done gradually to avoid benzodiazepine withdrawal. Abrupt discontinuation in patients physically dependent on benzodiazepines can precipitate seizures, a risk entirely unrelated to dapagliflozin but one that clinicians managing this combination must keep in mind.

Special Populations

Patients With Heart Failure

Dapagliflozin is approved for heart failure with reduced ejection fraction based on the DAPA-HF trial (N=4,744), which demonstrated a 26% relative risk reduction in the composite of worsening heart failure or cardiovascular death versus placebo (hazard ratio 0.74; 95% CI 0.65 to 0.85; P<0.001). [11] Benzodiazepines carry a specific concern in this population: they depress respiratory drive and may worsen sleep-disordered breathing, which is common in heart failure. Clinicians managing heart failure patients on dapagliflozin should use benzodiazepines only when no safer alternative exists and should document the rationale.

Patients With Chronic Kidney Disease

In the DAPA-CKD trial, dapagliflozin reduced the risk of sustained eGFR decline of 50% or greater, end-stage kidney disease, or renal or cardiovascular death by 39% versus placebo (hazard ratio 0.61; 95% CI 0.51 to 0.72; P<0.001). [8] CKD patients often have altered drug clearance. Benzodiazepines that rely on renal excretion of active metabolites, such as diazepam's metabolite desmethyldiazepam, may accumulate in moderate-to-severe CKD. This accumulation independently increases fall and CNS-depression risk, compounding any pharmacodynamic concern from dapagliflozin's volume effects.

Patients With Type 2 Diabetes Managed With Insulin

Insulin-treated type 2 diabetes patients represent the highest-risk subgroup for benzodiazepine co-prescribing alongside dapagliflozin. Dapagliflozin's glucose-lowering effect combined with insulin's direct hypoglycemic action creates a background risk of low glucose. Benzodiazepine sedation then reduces the patient's ability to recognize and respond to that low glucose. A 2020 systematic review in Diabetes Care identified CNS-active sedatives as an independent risk factor for severe hypoglycemia in insulin-treated patients, with an odds ratio of 2.1 (95% CI 1.4 to 3.1). [6]

Summary of the Interaction Classification

Pharmacokinetic interaction: absent. The UGT1A9 and CYP3A4/UGT2B7 pathways do not overlap in a clinically meaningful way for this combination.

Pharmacodynamic interaction: present and clinically manageable. The interaction is best classified as moderate in real-world frail or elderly patients with polypharmacy, and low in healthy younger adults on monotherapy for a single indication.

The severity classification shifts upward with each of the following risk factors: age above 65, eGFR below 45 mL/min/1.73 m², concurrent insulin or sulfonylurea use, long-acting benzodiazepine selection, baseline systolic blood pressure below 110 mmHg, and history of falls.